Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983658 | 0.89 | TSHR (0.32) | LMNA | |
| SCHEMBL11027655 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2KCNH2LMNAPOLBHDAC3 | |
| SCHEMBL15648671 | 0.82 | BDKRB2 (0.36) | SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL15648819 | 0.82 | BDKRB2 (0.36) | SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL11021373 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2KCNH2LMNAPOLBHDAC3 | |
| SCHEMBL1452840 | 0.80 | HTT (0.38) | SMN1; SMN2KCNH2LMNAALDH1A1HPGD | |
| SCHEMBL4738020 | 0.79 | THRA (0.32) | SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL2721463 | 0.78 | CYP1A2 (0.39) | SMN1; SMN2LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL154543 | 0.78 | TP53 (0.37) | SMN1; SMN2LMNAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1096789 | 0.78 | HTR7 (0.41) | LMNAHDAC3HDAC1HDAC2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10025284-A | — | — | None | — | — | JP | disclosed |
| CN-108864173-B | Process for converting substituted sodium arylsulfinates into aryltri-n-butyltin | 天津师范大学 | 2020-07-21 | — | — | CN | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2014022377-A1 | MEMBRANES AND COATINGS MADE FROM MIXTURES INCLUDING IONIC LIQUIDS HAVING SILICON-BONDED HYDROLYZABLE GROUPS | DOW CORNING CORPORATION (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-6620940-B1 | Heterocyclic nitrogen/sulfur compounds used as chemical intermediates for drugs such as 3-chloro-4-(furan-2-yl)-1,2,5 -thiadiazole | ELI LILLY AND COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-6605604-B1 | Tumour necrosis factor alpha release inhibitors; efficiency treatment of cancers, rheumatic diseases, arthritis, ulcers, atherosclerosis, asthma | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
| US-5770617-A | Terbenzimidazoles useful as antifungal agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-06-23 | — | — | US | disclosed |
| US-5767142-A | INHIBITION OF MAMMALIAN TUMOR CELL GROWTH | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0839140-A1 | TRIBENZIMIDAZOLES USEFUL AS TOPOISOMERASE I INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0825187-A1 | Condensed pyridazinyl guanidines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
| JP-H1025284-A | PRODUCTION OF 1,2,5-THIADIAZOLE DERIVATIVE | TOSOH CORP | 1998-01-27 | — | — | JP | disclosed |
| WO-1996036612-A1 | TRIBENZIMIDAZOLES USEFUL AS TOPOISOMERASE I INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | SMN1; SMN2 2829/4885KCNH2 3432/4885LMNA 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.